Trending NewsTrending NewsNASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $35.89 -0.25 (-0.69%) Closing price 04:00 PM EasternExtended Trading$36.60 +0.70 (+1.96%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harrow Stock (NASDAQ:HROW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Harrow alerts:Sign Up Key Stats Today's Range$35.60▼$36.9350-Day Range$25.13▼$36.1452-Week Range$20.85▼$59.23Volume482,017 shsAverage Volume500,180 shsMarket Capitalization$1.32 billionP/E RatioN/ADividend YieldN/APrice Target$63.83Consensus RatingBuy Company Overview Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee. Read More Harrow Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreHROW MarketRank™: Harrow scored higher than 47% of companies evaluated by MarketBeat, and ranked 609th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHarrow has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarrow has only been the subject of 4 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Harrow are expected to grow in the coming year, from ($0.53) to $0.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -64.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -64.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 18.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.27% of the float of Harrow has been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Harrow has recently increased by 1.72%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.27% of the float of Harrow has been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Harrow has recently increased by 1.72%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.40 News SentimentHarrow has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Harrow this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows2 people have added Harrow to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have not sold or bought any company stock.Percentage Held by Insiders15.16% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Email Address HROW Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROWJuly 18 at 12:00 PM | globenewswire.comWhat is William Blair's Forecast for Harrow Q2 Earnings?July 18 at 2:15 AM | americanbankingnews.comThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the same point in every cycle when crypto enters its most explosive phase — and two experts are showing how to ride it. Inside The Crypto Code Workshop, you’ll get their step-by-step system and $10 in free Bitcoin for attending.July 18 at 2:00 AM | Crypto Swap Profits (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROWJuly 17 at 10:00 AM | prnewswire.comSamsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United StatesJuly 17 at 7:00 AM | businesswire.comHarrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United StatesJuly 17 at 7:00 AM | businesswire.comFY2026 Earnings Forecast for Harrow Issued By William BlairJuly 17 at 3:49 AM | americanbankingnews.comHROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law FirmJuly 15 at 10:38 AM | prnewswire.comSee More Headlines HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $33.55 at the beginning of the year. Since then, HROW stock has increased by 7.0% and is now trading at $35.89. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.40. The firm had revenue of $47.83 million for the quarter, compared to analyst estimates of $57 million. Harrow had a negative trailing twelve-month return on equity of 25.01% and a negative net margin of 10.19%. Read the conference call transcript. Who are Harrow's major shareholders? Harrow's top institutional investors include Maridea Wealth Management LLC (0.02%) and SJS Investment Consulting Inc. (0.02%). Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Martin A Makary, Richard L Md Lindstrom and Horn R Lawrence Van. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/08/2025Today7/18/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees180Year FoundedN/APrice Target and Rating Average Price Target for Harrow$63.83 High Price Target$76.00 Low Price Target$55.00 Potential Upside/Downside+77.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.48 million Net Margins-10.19% Pretax Margin-10.12% Return on Equity-25.01% Return on Assets-4.27% Debt Debt-to-Equity Ratio2.01 Current Ratio0.91 Quick Ratio0.85 Sales & Book Value Annual Sales$199.61 million Price / Sales6.63 Cash Flow$0.14 per share Price / Cash Flow252.67 Book Value$1.95 per share Price / Book18.50Miscellaneous Outstanding Shares36,690,000Free Float31,124,000Market Cap$1.32 billion OptionableOptionable Beta0.41 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:HROW) was last updated on 7/18/2025 by MarketBeat.com Staff From Our Partners[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredWhen your faith is put to the test, what will you do?Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.